Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Lodderomyces elongisporus Nascent polypeptide-associated complex subunit alpha (EGD2) CSB-YP015403LLV
CSB-EP015403LLV
CSB-BP015403LLV
CSB-MP015403LLV
CSB-EP015403LLV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Lodderomyces elongisporus Pescadillo homolog (NOP7), partial CSB-YP017791LLV
CSB-EP017791LLV
CSB-BP017791LLV
CSB-MP017791LLV
CSB-EP017791LLV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Lodderomyces elongisporus Histone H3.3 (HHT3) CSB-YP010109LLV
CSB-EP010109LLV
CSB-BP010109LLV
CSB-MP010109LLV
CSB-EP010109LLV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Lodderomyces elongisporus Eukaryotic translation initiation factor 3 subunit A (TIF32), partial CSB-YP007543LLV
CSB-EP007543LLV
CSB-BP007543LLV
CSB-MP007543LLV
CSB-EP007543LLV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Lodderomyces elongisporus Eukaryotic translation initiation factor 3 subunit G (TIF35) CSB-YP007536LLV
CSB-EP007536LLV
CSB-BP007536LLV
CSB-MP007536LLV
CSB-EP007536LLV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Lodderomyces elongisporus Eukaryotic translation initiation factor 3 subunit C (NIP1), partial CSB-YP007531LLV
CSB-EP007531LLV
CSB-BP007531LLV
CSB-MP007531LLV
CSB-EP007531LLV-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Lodderomyces elongisporus NADH-cytochrome b5 reductase 2 (MCR1), partial CSB-YP006319LLV1
CSB-EP006319LLV1
CSB-BP006319LLV1
CSB-MP006319LLV1
CSB-EP006319LLV1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium sp. Succinyl-CoA ligase [ADP-forming] subunit beta (sucC) CSB-YP022917BPE
CSB-EP022917BPE
CSB-BP022917BPE
CSB-MP022917BPE
CSB-EP022917BPE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium sp. Protoheme IX farnesyltransferase (ctaB), partial CSB-YP005824BPE
CSB-EP005824BPE
CSB-BP005824BPE
CSB-MP005824BPE
CSB-EP005824BPE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium sp. Serine hydroxymethyltransferase (glyA) CSB-YP021274BPE
CSB-EP021274BPE
CSB-BP021274BPE
CSB-MP021274BPE
CSB-EP021274BPE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Bradyrhizobium sp. Methionyl-tRNA formyltransferase (fmt) CSB-YP015150BPE
CSB-EP015150BPE
CSB-BP015150BPE
CSB-MP015150BPE
CSB-EP015150BPE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Dichelobacter nodosus Elongation factor Ts (tsf) CSB-YP025124DHZ
CSB-EP025124DHZ
CSB-BP025124DHZ
CSB-MP025124DHZ
CSB-EP025124DHZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Dichelobacter nodosus Translation initiation factor IF-2 (infB), partial CSB-YP015164DHZ
CSB-EP015164DHZ
CSB-BP015164DHZ
CSB-MP015164DHZ
CSB-EP015164DHZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Dichelobacter nodosus Succinyl-CoA ligase [ADP-forming] subunit beta (sucC) CSB-YP022917DHZ
CSB-EP022917DHZ
CSB-BP022917DHZ
CSB-MP022917DHZ
CSB-EP022917DHZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Glycine dehydrogenase [decarboxylating] (gcvP), partial CSB-YP009493VEY
CSB-EP009493VEY
CSB-BP009493VEY
CSB-MP009493VEY
CSB-EP009493VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Nicotinate phosphoribosyltransferase (pncB) CSB-YP015451VEY
CSB-EP015451VEY
CSB-BP015451VEY
CSB-MP015451VEY
CSB-EP015451VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 tRNA pseudouridine synthase A (truA) CSB-YP019086VEY
CSB-EP019086VEY
CSB-BP019086VEY
CSB-MP019086VEY
CSB-EP019086VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Aldehyde dehydrogenase (aldA), partial CSB-YP001572VEY
CSB-EP001572VEY
CSB-BP001572VEY
CSB-MP001572VEY
CSB-EP001572VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 ATP synthase subunit beta (atpD) CSB-YP002350VEY
CSB-EP002350VEY
CSB-BP002350VEY
CSB-MP002350VEY
CSB-EP002350VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Vibrio cholerae serotype O1 Argininosuccinate synthase (argG) CSB-YP002234VEY
CSB-EP002234VEY
CSB-BP002234VEY
CSB-MP002234VEY
CSB-EP002234VEY-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>